ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs57.3 M49.04 M43.28 M44.95 M46.01 M37.83 M172.08 MRecherche et développement76.38 M70.92 M53.37 M69.35 M50.13 M49.92 M222.77 MRésultat d'exploitation-103.61 M-88.97 M-65.54 M-90.02 M-78.75 M-71.37 M-305.68 MTotal des produits hors exploitation-16.8 M-5.59 M4.73 M12.95 M-26.82 M-5.98 M-15.12 MCharges d'intérêts, nettes des intérêts capitalisés31.37 M——————Résultat hors exploitation, hors charges d'intérêts-43.91 M-3.69 M-229 K3.68 M-16.52 M-1.21 M-14.28 MRevenus/dépenses exceptionnels-4.25 M-1.9 M4.96 M9.26 M-10.29 M-4.76 M-837 KRésultat avant impôts-107.86 M-90.87 M-60.58 M-80.75 M-89.04 M-76.14 M-306.52 MPart des actionnaires dans le résultat0———0——Impôts-325 K88 K-283 K1 000-643 K-80 K-1 MIntérêts ne donnant pas le contrôle / intérêts minoritaires0——————Autres produits/charges après impôts-569 K-149 K103 K-1.56 M-453 K-185 K-2.1 MRésultat net avant activités abandonnées-107.53 M-90.96 M-60.3 M-80.75 M-80.75 M-76.06 M-297.87 MActivités abandonnées—————-6.53 M—Résultat net-107.53 M-90.96 M-60.3 M-80.75 M-80.75 M-82.59 M-304.39 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-106.86 M-90.96 M-60.3 M-80.75 M-80.75 M-82.59 M-304.39 MBénéfice par action de base (BPA de base)-1.92-1.68-1.1-1.45-1.41-1.39-5.35Bénéfice par action dilué (BPA dilué)-1.91-1.68-1.1-1.45-1.41-1.39-5.35Nombre moyen d'actions de base en circulation51.89 M54.24 M54.86 M55.63 M55.46 M59.56 M—Nombre d'actions en circulation après dilution51.89 M54.24 M54.86 M55.63 M55.46 M59.56 M—EBITDA-85.61 M-78.19 M-54.76 M-79.67 M-52.05 M-63.58 M-250.06 MEBIT-103.61 M-82.89 M-59.46 M-84.28 M-70.75 M-67.78 M-282.26 MCoût des ventes—————3.1 M—Autres coûts des ventes———————Amortissements (flux de trésorerie)18 M4.7 M4.7 M4.6 M18.7 M4.2 M32.2 M
Ginkgo Bioworks Holdings, Inc. Class A Common Stock
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.